What the infectious disease physician needs to know about pegylated interferon and ribavirin. [Review]

MedStar author(s):
Citation: Clinical Infectious Diseases. 56(11):1629-36, 2013 Jun.PMID: 23429551Institution: MedStar Washington Hospital CenterDepartment: Medicine/GastroenterologyForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., Extramural | Research Support, N.I.H., Intramural | ReviewSubject headings: *Antiviral Agents/pk [Pharmacokinetics] | *Hepatitis C, Chronic/dt [Drug Therapy] | *Hepatitis C, Chronic/me [Metabolism] | *Interferons/pk [Pharmacokinetics] | *Polyethylene Glycols/pk [Pharmacokinetics] | *Ribavirin/pk [Pharmacokinetics] | Antiviral Agents/ae [Adverse Effects] | Humans | Infectious Disease Medicine | Interferons/ae [Adverse Effects] | Polyethylene Glycols/ae [Adverse Effects] | Ribavirin/ae [Adverse Effects]Local holdings: Available online from MWHC library: June 1997 - present, Available in print through MWHC library: 1999 - Winter 2007ISSN:
  • 1058-4838
Name of journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAbstract: The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.All authors: Gara N, Ghany MGDigital Object Identifier: Date added to catalog: 2014-04-04
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 23429551

Available online from MWHC library: June 1997 - present, Available in print through MWHC library: 1999 - Winter 2007

The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.

English

Powered by Koha